EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes of Fontan‐Associated Hepatocellular Carcinoma: a Single‐Center Retrospective Study

Tomomi Kogiso iD, Sumire Takano, Yuri Ogasawara, Makiko Taniai, Eriko Shimada, Kei Inai, Haruko Numajiri, Yusuke Ome, Shunichi Ariizumi iD, Goro Honda, Sawa Kono, Yaichiro Hashimoto und 2 weitere

Journal of Gastroenterology and Hepatology · 2026-03 · 41 (3) · 1052-1064

DOI: 10.1111/jgh.70280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 11.02.2026. Verfasst von Tomomi Kogiso und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Fontan Procedure, Carcinoma, Hepatocellular, Liver Neoplasms, Postoperative Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Center for Global Health and Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fontan‐associated liver disease (FALD) is a long‐term complication after Fontan surgery, and the development of hepatocellular carcinoma (HCC) in relatively young patients has become a major clinical concern. This study aimed to clarify the diagnostic triggers, clinicopathological characteristics, treatment strategies, and outcomes of FALD‐HCC.

Methods

We retrospectively reviewed 297 patients with FALD who visited our department between 2003 and 2025. Among them, 28 patients (9.4%) developed HCC. Diagnostic triggers, tumor characteristics, initial treatment modalities, and clinical courses were analyzed.

Results

HCC developed at a median age of 32.6 years, with an interval of 26.1 years after Fontan surgery. Diagnosis was triggered by tumor marker elevation, including alpha‐fetoprotein and/or des‐gamma‐carboxy prothrombin, in 46.4% of patients, routine surveillance imaging in 35.7%, and symptom‐driven imaging in 17.9%. Most patients had a single tumor, frequently located in the peripheral liver. At diagnosis, 71.5% were classified as stage I or II disease. Histological evaluation, available in selected cases, revealed variable tumor differentiation and advanced fibrosis in noncancerous liver tissue. Initial treatments included hepatic resection, transcatheter arterial chemoembolization, stereotactic body radiotherapy, proton beam therapy, systemic therapy, or palliative care alone in patients with advanced liver failure. Three‐year survival rates were favorable, reaching 100% in patients treated with hepatic resection or stereotactic body radiotherapy.

Conclusions

When FALD‐HCC was detected at an early stage through surveillance, a broad range of treatment options, including locoregional therapies, could be applied and were associated with favorable clinical outcomes. Although selection bias limits direct comparison, treatment of FALD‐HCC should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fontan ProcedureCarcinoma, HepatocellularLiver NeoplasmsPostoperative ComplicationsHumansRetrospective StudiesFemaleMaleTreatment OutcomeAdultAdolescentBiomarkers, TumorYoung AdultTime FactorsChildMiddle Agedalpha-Fetoproteins

Stichwörter der Autor:innen

Fontan surgeryFontan‐associated liver diseasehepatocellular carcinomatreatment

Substanzen

Biomarkers, Tumoralpha-Fetoproteins

Autor:innen und Institutionen

  • Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
  • Pediatric Cardiology and Adult Congenital Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
  • The Proton Beam Therapy Center of the University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.
  • Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Radiation Oncology, Tokyo Women's Medical University, Tokyo, Japan.
  • Japan Community Health Care Organization Tokyo Joto Hospital, Tokyo, Japan.

ORCID-Profile: Tomomi Kogiso, Shunichi Ariizumi, Katsutoshi Tokushige

Förderung

  • National Center for Global Health and Medicine

Zitieren

APA

Kogiso, T., Takano, S., Ogasawara, Y., Taniai, M., Shimada, E., Inai, K., Numajiri, H., Ome, Y., Ariizumi, S., Honda, G., Kono, S., Hashimoto, Y., Tokushige, K., & Nakai, Y. (2026). Clinical Outcomes of Fontan‐Associated Hepatocellular Carcinoma: a Single‐Center Retrospective Study. Journal of Gastroenterology and Hepatology, 41(3), 1052-1064. https://doi.org/10.1111/jgh.70280

Vancouver

Kogiso T, Takano S, Ogasawara Y, Taniai M, Shimada E, Inai K, et al. Clinical Outcomes of Fontan‐Associated Hepatocellular Carcinoma: a Single‐Center Retrospective Study. Journal of Gastroenterology and Hepatology. 2026;41(3):1052-1064. doi:10.1111/jgh.70280

BibTeX
@article{Kogiso2026,
  author = {Kogiso, Tomomi and Takano, Sumire and Ogasawara, Yuri and Taniai, Makiko and Shimada, Eriko and Inai, Kei and Numajiri, Haruko and Ome, Yusuke and Ariizumi, Shunichi and Honda, Goro and Kono, Sawa and Hashimoto, Yaichiro and Tokushige, Katsutoshi and Nakai, Yousuke},
  title = {Clinical Outcomes of Fontan‐Associated Hepatocellular Carcinoma: a Single‐Center Retrospective Study},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {3},
  pages = {1052--1064},
  doi = {10.1111/jgh.70280}
}
Kostenlos starten →